AustralieFrV1, PascalFrancis, Corpus, bibRecord, 004380

Risk of second cancer among women with breast cancer

Identifieur interne : 004380 ( PascalFrancis/Corpus ); précédent : 004379; suivant : 004381

Risk of second cancer among women with breast cancer

Auteurs : Lene Mellemkjaer ; S Ren Friis ; J Rgen H. Olsen ; Ghislaine Scelo ; Kari Hemminki ; Elizabeth Tracey ; Aage Andersen ; David H. Brewster ; Eero Pukkala ; Mary L. Mcbride ; Erich V. Kliewer ; Jon M. Tonita ; Chia Kee-Seng ; Vera Pompe-Kirn ; Carmen Martos ; Jon G. Jonasson ; Paolo Boffetta ; Paul Brennan

Source :

International journal of cancer [ 0020-7136 ] ; 2006.

RBID : Pascal:06-0288916

Descripteurs français

Pascal (Inist)
- Second cancer, Facteur risque, Epidémiologie, Etats Unis, Femelle, Adulte, Canada, Etude multicentrique, Etude cohorte, Cancérologie, Europe, Australie, Cancer sein.

English descriptors

KwdEn :
- Adult, Australia, Breast cancer, Canada, Cancerology, Cohort study, Epidemiology, Europe, Female, Multicenter study, Risk factor, Second cancer, United States.

Abstract

A large number of women survive a diagnosis of breast cancer. Knowledge of their risk of developing a new primary cancer is important not only in relation to potential side effects of their cancer treatment, but also in relation to the possibility of shared etiology with other types of cancer. A cohort of 525,527 women with primary breast cancer was identified from 13 population-based cancer registries in Europe, Canada, Australia and Singapore, and followed for second primary cancers within the period 1943-2000. We used cancer incidence rates of first primary cancer for the calculation of standardized incidence ratios (SIRs) of second primary cancer. Risk of second primary breast cancer after various types of nonbreast cancer was also computed. For all second cancer sites combined, except contralateral breast cancer, we found a SIR of 1.25 (95% CI = 1.24-1.26) on the basis of 31,399 observed cases after first primary breast cancer. The overall risk increased with increasing time since breast cancer diagnosis and decreased by increasing age at breast cancer diagnosis. There were significant excesses of many different cancer sites; among these the excess was larger than 150 cases for stomach (SIR = 1.35), colorectal (SIR = 1.22), lung (SIR = 1.24), soft tissue sarcoma (SIR = 2.25), melanoma (SIR = 1.29), non-melanoma skin (SIR = 1.58), endometrium (SIR = 1.52), ovary (SIR = 1.48), kidney (SIR = 1.27), thyroid gland (SIR = 1.62) and leukaemia (SIR = 1.52). The excess of cancer after a breast cancer diagnosis is likely to be explained by treatment for breast cancer and by shared genetic or environmental risk factors, although the general excess of cancer suggests that there may be additional explanations such as increased surveillance and general cancer susceptibility.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0020-7136`
A02	`01`			`@0 IJCNAW`
A03		`1`		`@0 Int. j. cancer`
A05				`@2 118`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Risk of second cancer among women with breast cancer`
A11	`01`	`1`		`@1 MELLEMKJAER (Lene)`
A11	`02`	`1`		`@1 FRIIS (Søren)`
A11	`03`	`1`		`@1 OLSEN (Jørgen H.)`
A11	`04`	`1`		`@1 SCELO (Ghislaine)`
A11	`05`	`1`		`@1 HEMMINKI (Kari)`
A11	`06`	`1`		`@1 TRACEY (Elizabeth)`
A11	`07`	`1`		`@1 ANDERSEN (Aage)`
A11	`08`	`1`		`@1 BREWSTER (David H.)`
A11	`09`	`1`		`@1 PUKKALA (Eero)`
A11	`10`	`1`		`@1 MCBRIDE (Mary L.)`
A11	`11`	`1`		`@1 KLIEWER (Erich V.)`
A11	`12`	`1`		`@1 TONITA (Jon M.)`
A11	`13`	`1`		`@1 KEE-SENG (Chia)`
A11	`14`	`1`		`@1 POMPE-KIRN (Vera)`
A11	`15`	`1`		`@1 MARTOS (Carmen)`
A11	`16`	`1`		`@1 JONASSON (Jon G.)`
A11	`17`	`1`		`@1 BOFFETTA (Paolo)`
A11	`18`	`1`		`@1 BRENNAN (Paul)`
A14	`01`			`@1 Institute of Cancer Epidemiology, Danish Cancer Society @2 Copenhagen @3 DNK @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A14	`02`			`@1 Gene-Environment Epidemiology Group, Genetics and Epidemiology Cluster, International Agency for Research on Cancer (IARC) @2 Lyon @3 FRA @Z 4 aut. @Z 17 aut. @Z 18 aut.`
A14	`03`			`@1 Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ) @2 Heidelberg @3 DEU @Z 5 aut.`
A14	`04`			`@1 Department of Biosciences at Novum, Karolinska Institute @2 Hudinge @3 SWE @Z 5 aut.`
A14	`05`			`@1 New South Wales Cancer Registry @2 Eveleigh, NSW @3 AUS @Z 6 aut.`
A14	`06`			`@1 Institute of Population-Based Cancer Research @2 Oslo @3 NOR @Z 7 aut.`
A14	`07`			`@1 Scottish Cancer Registry Information Services, NHS National Services Scotland @2 Edinburgh, Scotland @3 GBR @Z 8 aut.`
A14	`08`			`@1 Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research @2 Helsinki @3 FIN @Z 9 aut.`
A14	`09`			`@1 Cancer Control Research Programme, British Columbia Cancer Agency @2 Vancouver, BC @3 CAN @Z 10 aut.`
A14	`10`			`@1 Epidemiology and Cancer Registry, CancerCare Manitoba @2 Winnipeg, MB @3 CAN @Z 11 aut.`
A14	`11`			`@1 Community Health Sciences, University of Manitoba @2 Winnipeg, MB @3 CAN @Z 11 aut.`
A14	`12`			`@1 Program Evaluation and Surveillance, Saskatchewan Cancer Agency @2 Regina, SK @3 CAN @Z 12 aut.`
A14	`13`			`@1 Center for Molecular Epidemiology @3 SGP @Z 13 aut.`
A14	`14`			`@1 Cancer Registry of Slovenia, institute of Oncology @2 Ljubljana @3 SVN @Z 14 aut.`
A14	`15`			`@1 Cancer Registry of Zaragoza, Health Department of Aragon Government @2 Zaragoza @3 ESP @Z 15 aut.`
A14	`16`			`@1 Icelandic Cancer Registry, Icelandic Cancer Society @2 Reykjavik @3 ISL @Z 16 aut.`
A14	`17`			`@1 The Medical Faculty, University of Iceland @2 Reykjavik @3 ISL @Z 16 aut.`
A20				`@1 2285-2292`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 13027 @5 354000156755570230`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 41 ref.`
A47	`01`	`1`		`@0 06-0288916`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 International journal of cancer`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 A large number of women survive a diagnosis of breast cancer. Knowledge of their risk of developing a new primary cancer is important not only in relation to potential side effects of their cancer treatment, but also in relation to the possibility of shared etiology with other types of cancer. A cohort of 525,527 women with primary breast cancer was identified from 13 population-based cancer registries in Europe, Canada, Australia and Singapore, and followed for second primary cancers within the period 1943-2000. We used cancer incidence rates of first primary cancer for the calculation of standardized incidence ratios (SIRs) of second primary cancer. Risk of second primary breast cancer after various types of nonbreast cancer was also computed. For all second cancer sites combined, except contralateral breast cancer, we found a SIR of 1.25 (95% CI = 1.24-1.26) on the basis of 31,399 observed cases after first primary breast cancer. The overall risk increased with increasing time since breast cancer diagnosis and decreased by increasing age at breast cancer diagnosis. There were significant excesses of many different cancer sites; among these the excess was larger than 150 cases for stomach (SIR = 1.35), colorectal (SIR = 1.22), lung (SIR = 1.24), soft tissue sarcoma (SIR = 2.25), melanoma (SIR = 1.29), non-melanoma skin (SIR = 1.58), endometrium (SIR = 1.52), ovary (SIR = 1.48), kidney (SIR = 1.27), thyroid gland (SIR = 1.62) and leukaemia (SIR = 1.52). The excess of cancer after a breast cancer diagnosis is likely to be explained by treatment for breast cancer and by shared genetic or environmental risk factors, although the general excess of cancer suggests that there may be additional explanations such as increased surveillance and general cancer susceptibility.
C02	`01`	`X`		`@0 002B04`
C02	`02`	`X`		`@0 002B20E02`
C02	`03`	`X`		`@0 235`
C03	`01`	`X`	`FRE`	`@0 Second cancer @5 01`
C03	`01`	`X`	`ENG`	`@0 Second cancer @5 01`
C03	`01`	`X`	`SPA`	`@0 Segundo cáncer @5 01`
C03	`02`	`X`	`FRE`	`@0 Facteur risque @5 02`
C03	`02`	`X`	`ENG`	`@0 Risk factor @5 02`
C03	`02`	`X`	`SPA`	`@0 Factor riesgo @5 02`
C03	`03`	`X`	`FRE`	`@0 Epidémiologie @5 03`
C03	`03`	`X`	`ENG`	`@0 Epidemiology @5 03`
C03	`03`	`X`	`SPA`	`@0 Epidemiología @5 03`
C03	`04`	`X`	`FRE`	`@0 Etats Unis @2 NG @5 05`
C03	`04`	`X`	`ENG`	`@0 United States @2 NG @5 05`
C03	`04`	`X`	`SPA`	`@0 Estados Unidos @2 NG @5 05`
C03	`05`	`X`	`FRE`	`@0 Femelle @5 06`
C03	`05`	`X`	`ENG`	`@0 Female @5 06`
C03	`05`	`X`	`SPA`	`@0 Hembra @5 06`
C03	`06`	`X`	`FRE`	`@0 Adulte @5 08`
C03	`06`	`X`	`ENG`	`@0 Adult @5 08`
C03	`06`	`X`	`SPA`	`@0 Adulto @5 08`
C03	`07`	`X`	`FRE`	`@0 Canada @2 NG @5 09`
C03	`07`	`X`	`ENG`	`@0 Canada @2 NG @5 09`
C03	`07`	`X`	`SPA`	`@0 Canadá @2 NG @5 09`
C03	`08`	`X`	`FRE`	`@0 Etude multicentrique @5 11`
C03	`08`	`X`	`ENG`	`@0 Multicenter study @5 11`
C03	`08`	`X`	`SPA`	`@0 Estudio multicéntrico @5 11`
C03	`09`	`X`	`FRE`	`@0 Etude cohorte @5 12`
C03	`09`	`X`	`ENG`	`@0 Cohort study @5 12`
C03	`09`	`X`	`SPA`	`@0 Estudio cohorte @5 12`
C03	`10`	`X`	`FRE`	`@0 Cancérologie @5 17`
C03	`10`	`X`	`ENG`	`@0 Cancerology @5 17`
C03	`10`	`X`	`SPA`	`@0 Cancerología @5 17`
C03	`11`	`X`	`FRE`	`@0 Europe @2 NG @5 18`
C03	`11`	`X`	`ENG`	`@0 Europe @2 NG @5 18`
C03	`11`	`X`	`SPA`	`@0 Europa @2 NG @5 18`
C03	`12`	`X`	`FRE`	`@0 Australie @2 NG @5 19`
C03	`12`	`X`	`ENG`	`@0 Australia @2 NG @5 19`
C03	`12`	`X`	`SPA`	`@0 Australia @2 NG @5 19`
C03	`13`	`X`	`FRE`	`@0 Cancer sein @4 CD @5 96`
C03	`13`	`X`	`ENG`	`@0 Breast cancer @4 CD @5 96`
C03	`13`	`X`	`SPA`	`@0 Cáncer pecho @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Amérique du Nord @2 NG`
C07	`01`	`X`	`ENG`	`@0 North America @2 NG`
C07	`01`	`X`	`SPA`	`@0 America del norte @2 NG`
C07	`02`	`X`	`FRE`	`@0 Amérique @2 NG`
C07	`02`	`X`	`ENG`	`@0 America @2 NG`
C07	`02`	`X`	`SPA`	`@0 America @2 NG`
C07	`03`	`X`	`FRE`	`@0 Homme`
C07	`03`	`X`	`ENG`	`@0 Human`
C07	`03`	`X`	`SPA`	`@0 Hombre`
C07	`04`	`X`	`FRE`	`@0 Océanie @2 NG`
C07	`04`	`X`	`ENG`	`@0 Oceania @2 NG`
C07	`04`	`X`	`SPA`	`@0 Oceania @2 NG`
C07	`05`	`X`	`FRE`	`@0 Tumeur maligne @5 37`
C07	`05`	`X`	`ENG`	`@0 Malignant tumor @5 37`
C07	`05`	`X`	`SPA`	`@0 Tumor maligno @5 37`
C07	`06`	`X`	`FRE`	`@0 Glande mammaire pathologie @2 NM @5 38`
C07	`06`	`X`	`ENG`	`@0 Mammary gland diseases @2 NM @5 38`
C07	`06`	`X`	`SPA`	`@0 Glándula mamaria patología @2 NM @5 38`
C07	`07`	`X`	`FRE`	`@0 Santé publique @5 39`
C07	`07`	`X`	`ENG`	`@0 Public health @5 39`
C07	`07`	`X`	`SPA`	`@0 Salud pública @5 39`
N21				`@1 184`

Format Inist (serveur)

NO :	PASCAL 06-0288916 INIST
ET :	Risk of second cancer among women with breast cancer
AU :	MELLEMKJAER (Lene); FRIIS (Søren); OLSEN (Jørgen H.); SCELO (Ghislaine); HEMMINKI (Kari); TRACEY (Elizabeth); ANDERSEN (Aage); BREWSTER (David H.); PUKKALA (Eero); MCBRIDE (Mary L.); KLIEWER (Erich V.); TONITA (Jon M.); KEE-SENG (Chia); POMPE-KIRN (Vera); MARTOS (Carmen); JONASSON (Jon G.); BOFFETTA (Paolo); BRENNAN (Paul)
AF :	Institute of Cancer Epidemiology, Danish Cancer Society/Copenhagen/Danemark (1 aut., 2 aut., 3 aut.); Gene-Environment Epidemiology Group, Genetics and Epidemiology Cluster, International Agency for Research on Cancer (IARC)/Lyon/France (4 aut., 17 aut., 18 aut.); Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ)/Heidelberg/Allemagne (5 aut.); Department of Biosciences at Novum, Karolinska Institute/Hudinge/Suède (5 aut.); New South Wales Cancer Registry/Eveleigh, NSW/Australie (6 aut.); Institute of Population-Based Cancer Research/Oslo/Norvège (7 aut.); Scottish Cancer Registry Information Services, NHS National Services Scotland/Edinburgh, Scotland/Royaume-Uni (8 aut.); Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research/Helsinki/Finlande (9 aut.); Cancer Control Research Programme, British Columbia Cancer Agency/Vancouver, BC/Canada (10 aut.); Epidemiology and Cancer Registry, CancerCare Manitoba/Winnipeg, MB/Canada (11 aut.); Community Health Sciences, University of Manitoba/Winnipeg, MB/Canada (11 aut.); Program Evaluation and Surveillance, Saskatchewan Cancer Agency/Regina, SK/Canada (12 aut.); Center for Molecular Epidemiology/Singapour (13 aut.); Cancer Registry of Slovenia, institute of Oncology/Ljubljana/Slovénie (14 aut.); Cancer Registry of Zaragoza, Health Department of Aragon Government/Zaragoza/Espagne (15 aut.); Icelandic Cancer Registry, Icelandic Cancer Society/Reykjavik/Islande (16 aut.); The Medical Faculty, University of Iceland/Reykjavik/Islande (16 aut.)
DT :	Publication en série; Niveau analytique
SO :	International journal of cancer; ISSN 0020-7136; Coden IJCNAW; Etats-Unis; Da. 2006; Vol. 118; No. 9; Pp. 2285-2292; Bibl. 41 ref.
LA :	Anglais
EA :	A large number of women survive a diagnosis of breast cancer. Knowledge of their risk of developing a new primary cancer is important not only in relation to potential side effects of their cancer treatment, but also in relation to the possibility of shared etiology with other types of cancer. A cohort of 525,527 women with primary breast cancer was identified from 13 population-based cancer registries in Europe, Canada, Australia and Singapore, and followed for second primary cancers within the period 1943-2000. We used cancer incidence rates of first primary cancer for the calculation of standardized incidence ratios (SIRs) of second primary cancer. Risk of second primary breast cancer after various types of nonbreast cancer was also computed. For all second cancer sites combined, except contralateral breast cancer, we found a SIR of 1.25 (95% CI = 1.24-1.26) on the basis of 31,399 observed cases after first primary breast cancer. The overall risk increased with increasing time since breast cancer diagnosis and decreased by increasing age at breast cancer diagnosis. There were significant excesses of many different cancer sites; among these the excess was larger than 150 cases for stomach (SIR = 1.35), colorectal (SIR = 1.22), lung (SIR = 1.24), soft tissue sarcoma (SIR = 2.25), melanoma (SIR = 1.29), non-melanoma skin (SIR = 1.58), endometrium (SIR = 1.52), ovary (SIR = 1.48), kidney (SIR = 1.27), thyroid gland (SIR = 1.62) and leukaemia (SIR = 1.52). The excess of cancer after a breast cancer diagnosis is likely to be explained by treatment for breast cancer and by shared genetic or environmental risk factors, although the general excess of cancer suggests that there may be additional explanations such as increased surveillance and general cancer susceptibility.
CC :	002B04; 002B20E02; 235
FD :	Second cancer; Facteur risque; Epidémiologie; Etats Unis; Femelle; Adulte; Canada; Etude multicentrique; Etude cohorte; Cancérologie; Europe; Australie; Cancer sein
FG :	Amérique du Nord; Amérique; Homme; Océanie; Tumeur maligne; Glande mammaire pathologie; Santé publique
ED :	Second cancer; Risk factor; Epidemiology; United States; Female; Adult; Canada; Multicenter study; Cohort study; Cancerology; Europe; Australia; Breast cancer
EG :	North America; America; Human; Oceania; Malignant tumor; Mammary gland diseases; Public health
SD :	Segundo cáncer; Factor riesgo; Epidemiología; Estados Unidos; Hembra; Adulto; Canadá; Estudio multicéntrico; Estudio cohorte; Cancerología; Europa; Australia; Cáncer pecho
LO :	INIST-13027.354000156755570230
ID :	06-0288916

Links to Exploration step

Pascal:06-0288916

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Risk of second cancer among women with breast cancer</title>
<author><name sortKey="Mellemkjaer, Lene" sort="Mellemkjaer, Lene" uniqKey="Mellemkjaer L" first="Lene" last="Mellemkjaer">Lene Mellemkjaer</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Cancer Epidemiology, Danish Cancer Society</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Friis, S Ren" sort="Friis, S Ren" uniqKey="Friis S" first="S Ren" last="Friis">S Ren Friis</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Cancer Epidemiology, Danish Cancer Society</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Olsen, J Rgen H" sort="Olsen, J Rgen H" uniqKey="Olsen J" first="J Rgen H." last="Olsen">J Rgen H. Olsen</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Cancer Epidemiology, Danish Cancer Society</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Scelo, Ghislaine" sort="Scelo, Ghislaine" uniqKey="Scelo G" first="Ghislaine" last="Scelo">Ghislaine Scelo</name>
<affiliation><inist:fA14 i1="02"><s1>Gene-Environment Epidemiology Group, Genetics and Epidemiology Cluster, International Agency for Research on Cancer (IARC)</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hemminki, Kari" sort="Hemminki, Kari" uniqKey="Hemminki K" first="Kari" last="Hemminki">Kari Hemminki</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ)</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Biosciences at Novum, Karolinska Institute</s1>
<s2>Hudinge</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tracey, Elizabeth" sort="Tracey, Elizabeth" uniqKey="Tracey E" first="Elizabeth" last="Tracey">Elizabeth Tracey</name>
<affiliation><inist:fA14 i1="05"><s1>New South Wales Cancer Registry</s1>
<s2>Eveleigh, NSW</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Andersen, Aage" sort="Andersen, Aage" uniqKey="Andersen A" first="Aage" last="Andersen">Aage Andersen</name>
<affiliation><inist:fA14 i1="06"><s1>Institute of Population-Based Cancer Research</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brewster, David H" sort="Brewster, David H" uniqKey="Brewster D" first="David H." last="Brewster">David H. Brewster</name>
<affiliation><inist:fA14 i1="07"><s1>Scottish Cancer Registry Information Services, NHS National Services Scotland</s1>
<s2>Edinburgh, Scotland</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pukkala, Eero" sort="Pukkala, Eero" uniqKey="Pukkala E" first="Eero" last="Pukkala">Eero Pukkala</name>
<affiliation><inist:fA14 i1="08"><s1>Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcbride, Mary L" sort="Mcbride, Mary L" uniqKey="Mcbride M" first="Mary L." last="Mcbride">Mary L. Mcbride</name>
<affiliation><inist:fA14 i1="09"><s1>Cancer Control Research Programme, British Columbia Cancer Agency</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kliewer, Erich V" sort="Kliewer, Erich V" uniqKey="Kliewer E" first="Erich V." last="Kliewer">Erich V. Kliewer</name>
<affiliation><inist:fA14 i1="10"><s1>Epidemiology and Cancer Registry, CancerCare Manitoba</s1>
<s2>Winnipeg, MB</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="11"><s1>Community Health Sciences, University of Manitoba</s1>
<s2>Winnipeg, MB</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tonita, Jon M" sort="Tonita, Jon M" uniqKey="Tonita J" first="Jon M." last="Tonita">Jon M. Tonita</name>
<affiliation><inist:fA14 i1="12"><s1>Program Evaluation and Surveillance, Saskatchewan Cancer Agency</s1>
<s2>Regina, SK</s2>
<s3>CAN</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kee Seng, Chia" sort="Kee Seng, Chia" uniqKey="Kee Seng C" first="Chia" last="Kee-Seng">Chia Kee-Seng</name>
<affiliation><inist:fA14 i1="13"><s1>Center for Molecular Epidemiology</s1>
<s3>SGP</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pompe Kirn, Vera" sort="Pompe Kirn, Vera" uniqKey="Pompe Kirn V" first="Vera" last="Pompe-Kirn">Vera Pompe-Kirn</name>
<affiliation><inist:fA14 i1="14"><s1>Cancer Registry of Slovenia, institute of Oncology</s1>
<s2>Ljubljana</s2>
<s3>SVN</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martos, Carmen" sort="Martos, Carmen" uniqKey="Martos C" first="Carmen" last="Martos">Carmen Martos</name>
<affiliation><inist:fA14 i1="15"><s1>Cancer Registry of Zaragoza, Health Department of Aragon Government</s1>
<s2>Zaragoza</s2>
<s3>ESP</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jonasson, Jon G" sort="Jonasson, Jon G" uniqKey="Jonasson J" first="Jon G." last="Jonasson">Jon G. Jonasson</name>
<affiliation><inist:fA14 i1="16"><s1>Icelandic Cancer Registry, Icelandic Cancer Society</s1>
<s2>Reykjavik</s2>
<s3>ISL</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="17"><s1>The Medical Faculty, University of Iceland</s1>
<s2>Reykjavik</s2>
<s3>ISL</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Boffetta, Paolo" sort="Boffetta, Paolo" uniqKey="Boffetta P" first="Paolo" last="Boffetta">Paolo Boffetta</name>
<affiliation><inist:fA14 i1="02"><s1>Gene-Environment Epidemiology Group, Genetics and Epidemiology Cluster, International Agency for Research on Cancer (IARC)</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brennan, Paul" sort="Brennan, Paul" uniqKey="Brennan P" first="Paul" last="Brennan">Paul Brennan</name>
<affiliation><inist:fA14 i1="02"><s1>Gene-Environment Epidemiology Group, Genetics and Epidemiology Cluster, International Agency for Research on Cancer (IARC)</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0288916</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0288916 INIST</idno>
<idno type="RBID">Pascal:06-0288916</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">004380</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Risk of second cancer among women with breast cancer</title>
<author><name sortKey="Mellemkjaer, Lene" sort="Mellemkjaer, Lene" uniqKey="Mellemkjaer L" first="Lene" last="Mellemkjaer">Lene Mellemkjaer</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Cancer Epidemiology, Danish Cancer Society</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Friis, S Ren" sort="Friis, S Ren" uniqKey="Friis S" first="S Ren" last="Friis">S Ren Friis</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Cancer Epidemiology, Danish Cancer Society</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Olsen, J Rgen H" sort="Olsen, J Rgen H" uniqKey="Olsen J" first="J Rgen H." last="Olsen">J Rgen H. Olsen</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Cancer Epidemiology, Danish Cancer Society</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Scelo, Ghislaine" sort="Scelo, Ghislaine" uniqKey="Scelo G" first="Ghislaine" last="Scelo">Ghislaine Scelo</name>
<affiliation><inist:fA14 i1="02"><s1>Gene-Environment Epidemiology Group, Genetics and Epidemiology Cluster, International Agency for Research on Cancer (IARC)</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hemminki, Kari" sort="Hemminki, Kari" uniqKey="Hemminki K" first="Kari" last="Hemminki">Kari Hemminki</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ)</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Biosciences at Novum, Karolinska Institute</s1>
<s2>Hudinge</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tracey, Elizabeth" sort="Tracey, Elizabeth" uniqKey="Tracey E" first="Elizabeth" last="Tracey">Elizabeth Tracey</name>
<affiliation><inist:fA14 i1="05"><s1>New South Wales Cancer Registry</s1>
<s2>Eveleigh, NSW</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Andersen, Aage" sort="Andersen, Aage" uniqKey="Andersen A" first="Aage" last="Andersen">Aage Andersen</name>
<affiliation><inist:fA14 i1="06"><s1>Institute of Population-Based Cancer Research</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brewster, David H" sort="Brewster, David H" uniqKey="Brewster D" first="David H." last="Brewster">David H. Brewster</name>
<affiliation><inist:fA14 i1="07"><s1>Scottish Cancer Registry Information Services, NHS National Services Scotland</s1>
<s2>Edinburgh, Scotland</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pukkala, Eero" sort="Pukkala, Eero" uniqKey="Pukkala E" first="Eero" last="Pukkala">Eero Pukkala</name>
<affiliation><inist:fA14 i1="08"><s1>Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcbride, Mary L" sort="Mcbride, Mary L" uniqKey="Mcbride M" first="Mary L." last="Mcbride">Mary L. Mcbride</name>
<affiliation><inist:fA14 i1="09"><s1>Cancer Control Research Programme, British Columbia Cancer Agency</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kliewer, Erich V" sort="Kliewer, Erich V" uniqKey="Kliewer E" first="Erich V." last="Kliewer">Erich V. Kliewer</name>
<affiliation><inist:fA14 i1="10"><s1>Epidemiology and Cancer Registry, CancerCare Manitoba</s1>
<s2>Winnipeg, MB</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="11"><s1>Community Health Sciences, University of Manitoba</s1>
<s2>Winnipeg, MB</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tonita, Jon M" sort="Tonita, Jon M" uniqKey="Tonita J" first="Jon M." last="Tonita">Jon M. Tonita</name>
<affiliation><inist:fA14 i1="12"><s1>Program Evaluation and Surveillance, Saskatchewan Cancer Agency</s1>
<s2>Regina, SK</s2>
<s3>CAN</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kee Seng, Chia" sort="Kee Seng, Chia" uniqKey="Kee Seng C" first="Chia" last="Kee-Seng">Chia Kee-Seng</name>
<affiliation><inist:fA14 i1="13"><s1>Center for Molecular Epidemiology</s1>
<s3>SGP</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pompe Kirn, Vera" sort="Pompe Kirn, Vera" uniqKey="Pompe Kirn V" first="Vera" last="Pompe-Kirn">Vera Pompe-Kirn</name>
<affiliation><inist:fA14 i1="14"><s1>Cancer Registry of Slovenia, institute of Oncology</s1>
<s2>Ljubljana</s2>
<s3>SVN</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martos, Carmen" sort="Martos, Carmen" uniqKey="Martos C" first="Carmen" last="Martos">Carmen Martos</name>
<affiliation><inist:fA14 i1="15"><s1>Cancer Registry of Zaragoza, Health Department of Aragon Government</s1>
<s2>Zaragoza</s2>
<s3>ESP</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jonasson, Jon G" sort="Jonasson, Jon G" uniqKey="Jonasson J" first="Jon G." last="Jonasson">Jon G. Jonasson</name>
<affiliation><inist:fA14 i1="16"><s1>Icelandic Cancer Registry, Icelandic Cancer Society</s1>
<s2>Reykjavik</s2>
<s3>ISL</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="17"><s1>The Medical Faculty, University of Iceland</s1>
<s2>Reykjavik</s2>
<s3>ISL</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Boffetta, Paolo" sort="Boffetta, Paolo" uniqKey="Boffetta P" first="Paolo" last="Boffetta">Paolo Boffetta</name>
<affiliation><inist:fA14 i1="02"><s1>Gene-Environment Epidemiology Group, Genetics and Epidemiology Cluster, International Agency for Research on Cancer (IARC)</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brennan, Paul" sort="Brennan, Paul" uniqKey="Brennan P" first="Paul" last="Brennan">Paul Brennan</name>
<affiliation><inist:fA14 i1="02"><s1>Gene-Environment Epidemiology Group, Genetics and Epidemiology Cluster, International Agency for Research on Cancer (IARC)</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">International journal of cancer</title>
<title level="j" type="abbreviated">Int. j. cancer</title>
<idno type="ISSN">0020-7136</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">International journal of cancer</title>
<title level="j" type="abbreviated">Int. j. cancer</title>
<idno type="ISSN">0020-7136</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Australia</term>
<term>Breast cancer</term>
<term>Canada</term>
<term>Cancerology</term>
<term>Cohort study</term>
<term>Epidemiology</term>
<term>Europe</term>
<term>Female</term>
<term>Multicenter study</term>
<term>Risk factor</term>
<term>Second cancer</term>
<term>United States</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Second cancer</term>
<term>Facteur risque</term>
<term>Epidémiologie</term>
<term>Etats Unis</term>
<term>Femelle</term>
<term>Adulte</term>
<term>Canada</term>
<term>Etude multicentrique</term>
<term>Etude cohorte</term>
<term>Cancérologie</term>
<term>Europe</term>
<term>Australie</term>
<term>Cancer sein</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A large number of women survive a diagnosis of breast cancer. Knowledge of their risk of developing a new primary cancer is important not only in relation to potential side effects of their cancer treatment, but also in relation to the possibility of shared etiology with other types of cancer. A cohort of 525,527 women with primary breast cancer was identified from 13 population-based cancer registries in Europe, Canada, Australia and Singapore, and followed for second primary cancers within the period 1943-2000. We used cancer incidence rates of first primary cancer for the calculation of standardized incidence ratios (SIRs) of second primary cancer. Risk of second primary breast cancer after various types of nonbreast cancer was also computed. For all second cancer sites combined, except contralateral breast cancer, we found a SIR of 1.25 (95% CI = 1.24-1.26) on the basis of 31,399 observed cases after first primary breast cancer. The overall risk increased with increasing time since breast cancer diagnosis and decreased by increasing age at breast cancer diagnosis. There were significant excesses of many different cancer sites; among these the excess was larger than 150 cases for stomach (SIR = 1.35), colorectal (SIR = 1.22), lung (SIR = 1.24), soft tissue sarcoma (SIR = 2.25), melanoma (SIR = 1.29), non-melanoma skin (SIR = 1.58), endometrium (SIR = 1.52), ovary (SIR = 1.48), kidney (SIR = 1.27), thyroid gland (SIR = 1.62) and leukaemia (SIR = 1.52). The excess of cancer after a breast cancer diagnosis is likely to be explained by treatment for breast cancer and by shared genetic or environmental risk factors, although the general excess of cancer suggests that there may be additional explanations such as increased surveillance and general cancer susceptibility.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0020-7136</s0>
</fA01>
<fA02 i1="01"><s0>IJCNAW</s0>
</fA02>
<fA03 i2="1"><s0>Int. j. cancer</s0>
</fA03>
<fA05><s2>118</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Risk of second cancer among women with breast cancer</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MELLEMKJAER (Lene)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FRIIS (Søren)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>OLSEN (Jørgen H.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SCELO (Ghislaine)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HEMMINKI (Kari)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>TRACEY (Elizabeth)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ANDERSEN (Aage)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BREWSTER (David H.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>PUKKALA (Eero)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MCBRIDE (Mary L.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>KLIEWER (Erich V.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>TONITA (Jon M.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>KEE-SENG (Chia)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>POMPE-KIRN (Vera)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>MARTOS (Carmen)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>JONASSON (Jon G.)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>BOFFETTA (Paolo)</s1>
</fA11>
<fA11 i1="18" i2="1"><s1>BRENNAN (Paul)</s1>
</fA11>
<fA14 i1="01"><s1>Institute of Cancer Epidemiology, Danish Cancer Society</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Gene-Environment Epidemiology Group, Genetics and Epidemiology Cluster, International Agency for Research on Cancer (IARC)</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>17 aut.</sZ>
<sZ>18 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ)</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Biosciences at Novum, Karolinska Institute</s1>
<s2>Hudinge</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>New South Wales Cancer Registry</s1>
<s2>Eveleigh, NSW</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Institute of Population-Based Cancer Research</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Scottish Cancer Registry Information Services, NHS National Services Scotland</s1>
<s2>Edinburgh, Scotland</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Cancer Control Research Programme, British Columbia Cancer Agency</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Epidemiology and Cancer Registry, CancerCare Manitoba</s1>
<s2>Winnipeg, MB</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Community Health Sciences, University of Manitoba</s1>
<s2>Winnipeg, MB</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Program Evaluation and Surveillance, Saskatchewan Cancer Agency</s1>
<s2>Regina, SK</s2>
<s3>CAN</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Center for Molecular Epidemiology</s1>
<s3>SGP</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Cancer Registry of Slovenia, institute of Oncology</s1>
<s2>Ljubljana</s2>
<s3>SVN</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="15"><s1>Cancer Registry of Zaragoza, Health Department of Aragon Government</s1>
<s2>Zaragoza</s2>
<s3>ESP</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="16"><s1>Icelandic Cancer Registry, Icelandic Cancer Society</s1>
<s2>Reykjavik</s2>
<s3>ISL</s3>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="17"><s1>The Medical Faculty, University of Iceland</s1>
<s2>Reykjavik</s2>
<s3>ISL</s3>
<sZ>16 aut.</sZ>
</fA14>
<fA20><s1>2285-2292</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13027</s2>
<s5>354000156755570230</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>41 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0288916</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>International journal of cancer</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A large number of women survive a diagnosis of breast cancer. Knowledge of their risk of developing a new primary cancer is important not only in relation to potential side effects of their cancer treatment, but also in relation to the possibility of shared etiology with other types of cancer. A cohort of 525,527 women with primary breast cancer was identified from 13 population-based cancer registries in Europe, Canada, Australia and Singapore, and followed for second primary cancers within the period 1943-2000. We used cancer incidence rates of first primary cancer for the calculation of standardized incidence ratios (SIRs) of second primary cancer. Risk of second primary breast cancer after various types of nonbreast cancer was also computed. For all second cancer sites combined, except contralateral breast cancer, we found a SIR of 1.25 (95% CI = 1.24-1.26) on the basis of 31,399 observed cases after first primary breast cancer. The overall risk increased with increasing time since breast cancer diagnosis and decreased by increasing age at breast cancer diagnosis. There were significant excesses of many different cancer sites; among these the excess was larger than 150 cases for stomach (SIR = 1.35), colorectal (SIR = 1.22), lung (SIR = 1.24), soft tissue sarcoma (SIR = 2.25), melanoma (SIR = 1.29), non-melanoma skin (SIR = 1.58), endometrium (SIR = 1.52), ovary (SIR = 1.48), kidney (SIR = 1.27), thyroid gland (SIR = 1.62) and leukaemia (SIR = 1.52). The excess of cancer after a breast cancer diagnosis is likely to be explained by treatment for breast cancer and by shared genetic or environmental risk factors, although the general excess of cancer suggests that there may be additional explanations such as increased surveillance and general cancer susceptibility.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B20E02</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>235</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Second cancer</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Second cancer</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Segundo cáncer</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Epidémiologie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Epidemiology</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Epidemiología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Etats Unis</s0>
<s2>NG</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>United States</s0>
<s2>NG</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estados Unidos</s0>
<s2>NG</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Femelle</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Female</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hembra</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Adulte</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Adult</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Adulto</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Canada</s0>
<s2>NG</s2>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Canada</s0>
<s2>NG</s2>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Canadá</s0>
<s2>NG</s2>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Etude multicentrique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Multicenter study</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estudio multicéntrico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Etude cohorte</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Cohort study</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Estudio cohorte</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Cancérologie</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Cancerology</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Cancerología</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Europe</s0>
<s2>NG</s2>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Europe</s0>
<s2>NG</s2>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Europa</s0>
<s2>NG</s2>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Australie</s0>
<s2>NG</s2>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Australia</s0>
<s2>NG</s2>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Australia</s0>
<s2>NG</s2>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Cancer sein</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Breast cancer</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Cáncer pecho</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Amérique du Nord</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>North America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>America del norte</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Amérique</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Océanie</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Oceania</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Oceania</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Glande mammaire pathologie</s0>
<s2>NM</s2>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Santé publique</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Public health</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Salud pública</s0>
<s5>39</s5>
</fC07>
<fN21><s1>184</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 06-0288916 INIST</NO>
<ET>Risk of second cancer among women with breast cancer</ET>
<AU>MELLEMKJAER (Lene); FRIIS (Søren); OLSEN (Jørgen H.); SCELO (Ghislaine); HEMMINKI (Kari); TRACEY (Elizabeth); ANDERSEN (Aage); BREWSTER (David H.); PUKKALA (Eero); MCBRIDE (Mary L.); KLIEWER (Erich V.); TONITA (Jon M.); KEE-SENG (Chia); POMPE-KIRN (Vera); MARTOS (Carmen); JONASSON (Jon G.); BOFFETTA (Paolo); BRENNAN (Paul)</AU>
<AF>Institute of Cancer Epidemiology, Danish Cancer Society/Copenhagen/Danemark (1 aut., 2 aut., 3 aut.); Gene-Environment Epidemiology Group, Genetics and Epidemiology Cluster, International Agency for Research on Cancer (IARC)/Lyon/France (4 aut., 17 aut., 18 aut.); Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ)/Heidelberg/Allemagne (5 aut.); Department of Biosciences at Novum, Karolinska Institute/Hudinge/Suède (5 aut.); New South Wales Cancer Registry/Eveleigh, NSW/Australie (6 aut.); Institute of Population-Based Cancer Research/Oslo/Norvège (7 aut.); Scottish Cancer Registry Information Services, NHS National Services Scotland/Edinburgh, Scotland/Royaume-Uni (8 aut.); Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research/Helsinki/Finlande (9 aut.); Cancer Control Research Programme, British Columbia Cancer Agency/Vancouver, BC/Canada (10 aut.); Epidemiology and Cancer Registry, CancerCare Manitoba/Winnipeg, MB/Canada (11 aut.); Community Health Sciences, University of Manitoba/Winnipeg, MB/Canada (11 aut.); Program Evaluation and Surveillance, Saskatchewan Cancer Agency/Regina, SK/Canada (12 aut.); Center for Molecular Epidemiology/Singapour (13 aut.); Cancer Registry of Slovenia, institute of Oncology/Ljubljana/Slovénie (14 aut.); Cancer Registry of Zaragoza, Health Department of Aragon Government/Zaragoza/Espagne (15 aut.); Icelandic Cancer Registry, Icelandic Cancer Society/Reykjavik/Islande (16 aut.); The Medical Faculty, University of Iceland/Reykjavik/Islande (16 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>International journal of cancer; ISSN 0020-7136; Coden IJCNAW; Etats-Unis; Da. 2006; Vol. 118; No. 9; Pp. 2285-2292; Bibl. 41 ref.</SO>
<LA>Anglais</LA>
<EA>A large number of women survive a diagnosis of breast cancer. Knowledge of their risk of developing a new primary cancer is important not only in relation to potential side effects of their cancer treatment, but also in relation to the possibility of shared etiology with other types of cancer. A cohort of 525,527 women with primary breast cancer was identified from 13 population-based cancer registries in Europe, Canada, Australia and Singapore, and followed for second primary cancers within the period 1943-2000. We used cancer incidence rates of first primary cancer for the calculation of standardized incidence ratios (SIRs) of second primary cancer. Risk of second primary breast cancer after various types of nonbreast cancer was also computed. For all second cancer sites combined, except contralateral breast cancer, we found a SIR of 1.25 (95% CI = 1.24-1.26) on the basis of 31,399 observed cases after first primary breast cancer. The overall risk increased with increasing time since breast cancer diagnosis and decreased by increasing age at breast cancer diagnosis. There were significant excesses of many different cancer sites; among these the excess was larger than 150 cases for stomach (SIR = 1.35), colorectal (SIR = 1.22), lung (SIR = 1.24), soft tissue sarcoma (SIR = 2.25), melanoma (SIR = 1.29), non-melanoma skin (SIR = 1.58), endometrium (SIR = 1.52), ovary (SIR = 1.48), kidney (SIR = 1.27), thyroid gland (SIR = 1.62) and leukaemia (SIR = 1.52). The excess of cancer after a breast cancer diagnosis is likely to be explained by treatment for breast cancer and by shared genetic or environmental risk factors, although the general excess of cancer suggests that there may be additional explanations such as increased surveillance and general cancer susceptibility.</EA>
<CC>002B04; 002B20E02; 235</CC>
<FD>Second cancer; Facteur risque; Epidémiologie; Etats Unis; Femelle; Adulte; Canada; Etude multicentrique; Etude cohorte; Cancérologie; Europe; Australie; Cancer sein</FD>
<FG>Amérique du Nord; Amérique; Homme; Océanie; Tumeur maligne; Glande mammaire pathologie; Santé publique</FG>
<ED>Second cancer; Risk factor; Epidemiology; United States; Female; Adult; Canada; Multicenter study; Cohort study; Cancerology; Europe; Australia; Breast cancer</ED>
<EG>North America; America; Human; Oceania; Malignant tumor; Mammary gland diseases; Public health</EG>
<SD>Segundo cáncer; Factor riesgo; Epidemiología; Estados Unidos; Hembra; Adulto; Canadá; Estudio multicéntrico; Estudio cohorte; Cancerología; Europa; Australia; Cáncer pecho</SD>
<LO>INIST-13027.354000156755570230</LO>
<ID>06-0288916</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004380 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 004380 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0288916
   |texte=   Risk of second cancer among women with breast cancer
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Risk of second cancer among women with breast cancer

Risk of second cancer among women with breast cancer

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri